Sponsors (8)
Official title: To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of cannabinoid hemp products, and for other purposes.
Introduced January 22, 2026 by H. Morgan Griffith · Last progress January 22, 2026
The bill brings clearer federal definitions and stronger FDA/HHS tools to protect public health and give compliant businesses legal certainty, but it imposes significant compliance costs, potential product restrictions, and ongoing regulatory uncertainty that will most affect small hemp businesses and some consumers.
Manufacturers, retailers, and consumers get clearer federal rules and an HHS/FDA process for defining which chemicals are regulated as cannabinoids, reducing legal ambiguity for the marketplace.
Consumers and patients face lower health risk because the bill explicitly prohibits high‑risk products (e.g., high‑dose oral or inhalable cannabinoids, synthetic cannabinoids, animal‑food products) and gives FDA stronger inspection, detention, and seizure authority to remove unsafe cannabinoid hemp products from the market.
Compliant retailers and manufacturers can lawfully market cannabinoid hemp products that meet explicit federal manufacturing, testing, labeling, and age‑verification requirements, creating legal certainty for businesses that follow the rules.
Small hemp‑product manufacturers and retailers face substantial new costs and risks — including product reclassification or prohibition, testing/labeling and age‑verification compliance, detention/seizure exposure, and potential criminal penalties — that could cause lost sales, inventory disruption, or business closures.
The Secretary’s broad delegated authority to designate chemicals as cannabinoids could create ongoing regulatory uncertainty for companies until HHS updates and publishes lists, and may enable aggressive or unpredictable enforcement actions in ambiguous product categories.
Some consumers may lose access to cannabinoid products (previously sold as dietary supplements, edibles, or other consumer goods) if those products exceed new thresholds or are reclassified as prohibited, reducing consumer choice.
Based on analysis of 5 sections of legislative text.
Establishes FDA/HHS regulatory definitions, listing duties, enforcement authorities, and penalties for hemp-derived cannabinoid products entering interstate commerce.
Creates a new Federal regulatory framework for hemp-derived cannabinoid products by defining "cannabinoid" and "cannabinoid hemp product," assigning the Secretary of HHS/FDA duties to publish and update a list of regulated cannabinoid compounds, and bringing these products into the FD&C Act's prohibited acts, inspection, seizure, and criminal-penalty provisions. It also renumbers certain FD&C chapters for placement of the new regulatory provisions and preserves existing FDA and HHS authorities. The law requires an initial published list of cannabinoid compounds within one year, sets labeling/manufacturing/testing and retail-sale prohibitions (including sales to persons under 21), creates a new felony for knowing violations, expands detention/seizure powers for such products, and confirms these rules apply to products introduced into interstate commerce on or after enactment.